Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Catalent, Inc.

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. This chart compares the cost of revenue for Vertex Pharmaceuticals Incorporated and Catalent, Inc. over a decade, from 2014 to 2023. Catalent, Inc. has consistently shown a higher cost of revenue, peaking at approximately $3.4 billion in 2023, a staggering 180% increase from 2014. In contrast, Vertex Pharmaceuticals started with a modest cost of revenue, around $61 million in 2014, and saw a significant rise to $1.26 billion by 2023, marking an impressive 1,960% growth. This data highlights Catalent's steady expansion and Vertex's rapid scaling in cost management. However, the absence of data for Vertex in 2024 suggests a need for cautious interpretation. These insights provide a window into the financial strategies of two major players in the pharmaceutical industry, reflecting their operational priorities and market dynamics.

Key Insights

• Catalent's cost of revenue grew by 180% from 2014 to 2023.
• Vertex's cost of revenue surged by 1,960% in the same period.
• Missing data for Vertex in 2024 indicates potential reporting gaps.